These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 33741405

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
    Casey SL, Mitchell VA, Sokolaj EE, Winters BL, Vaughan CW.
    Int J Mol Sci; 2022 Aug 03; 23(15):. PubMed ID: 35955774
    [Abstract] [Full Text] [Related]

  • 4. Single and combined effects of Δ9 -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain.
    King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA, Ward SJ.
    Br J Pharmacol; 2017 Sep 03; 174(17):2832-2841. PubMed ID: 28548225
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. THC and gabapentin interactions in a mouse neuropathic pain model.
    Atwal N, Casey SL, Mitchell VA, Vaughan CW.
    Neuropharmacology; 2019 Jan 03; 144():115-121. PubMed ID: 30312630
    [Abstract] [Full Text] [Related]

  • 7. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T.
    Int J Neuropsychopharmacol; 2010 Aug 03; 13(7):861-76. PubMed ID: 19785914
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of cannabidiolic acid and ∆9-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain.
    Rock EM, Limebeer CL, Parker LA.
    Psychopharmacology (Berl); 2018 Nov 03; 235(11):3259-3271. PubMed ID: 30225659
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.
    Jones É, Vlachou S.
    Molecules; 2020 Oct 25; 25(21):. PubMed ID: 33113776
    [Abstract] [Full Text] [Related]

  • 14. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain.
    Hoggart B, Ratcliffe S, Ehler E, Simpson KH, Hovorka J, Lejčko J, Taylor L, Lauder H, Serpell M.
    J Neurol; 2015 Jan 25; 262(1):27-40. PubMed ID: 25270679
    [Abstract] [Full Text] [Related]

  • 15. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM.
    Ther Drug Monit; 2005 Dec 25; 27(6):799-810. PubMed ID: 16306858
    [Abstract] [Full Text] [Related]

  • 16. Use of cannabidiol (CBD) for the treatment of chronic pain.
    Urits I, Gress K, Charipova K, Habib K, Lee D, Lee C, Jung JW, Kassem H, Cornett E, Paladini A, Varrassi G, Kaye AD, Viswanath O.
    Best Pract Res Clin Anaesthesiol; 2020 Sep 25; 34(3):463-477. PubMed ID: 33004159
    [Abstract] [Full Text] [Related]

  • 17. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
    Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E.
    Eur J Pain; 2014 Aug 25; 18(7):999-1012. PubMed ID: 24420962
    [Abstract] [Full Text] [Related]

  • 18. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.
    Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, Wiley JL.
    Drug Alcohol Depend; 2008 Apr 01; 94(1-3):191-8. PubMed ID: 18206320
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT.
    J Pain Symptom Manage; 2013 Aug 01; 46(2):207-18. PubMed ID: 23141881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.